Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4640 studies found for:    lymphoma
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
2 Recruiting Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
3 Active, not recruiting Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
4 Active, not recruiting
Has Results
Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Lymphoplasmacytic Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Imexon
5 Completed An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.
Condition: Lymphoma
Intervention: Other: No intervention
6 Completed
Has Results
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Lymphoma, Large Cell;   Diffuse, Mantle Cell Lymphoma, Lymphoma;   Follicular Lymphoma;   Large B-Cell, Diffuse
Interventions: Drug: SyB L-0501;   Drug: Rituximab
7 Completed Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
8 Withdrawn Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma;   Lymphoma
Intervention: Procedure: PET/CT Scanning
9 Unknown  Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
10 Not yet recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Condition: Lymphoma
Intervention: Biological: DNA Vaccine
11 Terminated
Has Results
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Conditions: Cutaneous T-Cell Lymphoma;   Peripheral T-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: belinostat
12 Completed Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Condition: Lymphoma
Interventions: Drug: BIAXIN (CLARITHROMYCIN);   Drug: Biaxin (clarithromycin)
13 Recruiting Brazilian Network for Lymphoma Registry
Condition: Lymphoma
Intervention: Other: Observational, non-intervention
14 Terminated
Has Results
DepoCyt for Active Lymphomatous or Leukemic Meningitis
Conditions: Neoplastic Meningitis;   Lymphoma, B Cell
Intervention: Drug: cytarabine liposome injection
15 Recruiting Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
16 Completed Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Conditions: Hodgkin's Lymphoma;   Low Grade Lymphoma;   Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Diffuse Large Cell Lymphoma
Interventions: Drug: AMG 655;   Other: Vorinostat;   Other: Bortezomib
17 Recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: lenalidomide
18 Active, not recruiting A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: chemotherapy;   Drug: rituximab [MabThera/Rituxan];   Drug: RO5072759
19 Recruiting BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Conditions: Diffuse Large B-cell Lymphoma;   Hodgkin Lymphoma;   Metastatic Breast Cancer.;   Non-small Cell Lung Cancer
Intervention:
20 Completed Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Low Grade B-cell Lymphoma, Not Otherwise Specified;   Diffuse Large B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: Clofarabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years